Adverse events (AEs) related to the use of immune checkpoint inhibitor (ICI) therapy are
defined as immune-related (IR) AEs (irAEs). irAEs are graded according to the Common …

Auto-immune hemolytic anemia (AIHA) and hemophagocytic lymphohistiocytosis (HLH) are
both rare immune-related adverse events (irAEs) following treatment with immune …

The occurrence of second primary malignancies is becoming increasingly important among
cancer survivors. Melanoma, an aggressive neoplasm originating from the melanocytes, is …

Background Immune checkpoint inhibitors (ICIs) have revolutionized the management of
advanced melanoma (AM). However, data on ICI effectiveness have largely been restricted …

Chronic lymphocytic leukemia (CLL) is a B-cell-derived hematologic malignancy whose
progression depends on active B-cell receptor (BCR) signaling. Despite the spectacular …

With new, effective treatments for chronic lymphocytic leukaemia (CLL) the impact of second
malignancies is increasingly important. We performed a retrospective case‐controlled study …

Here, we present a novel case of a patient with chronic lymphocytic leukemia (CLL) who
received CTLA-4 and then PD-1 immune-checkpoint blockade (ICB) as treatment for …

Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy that is associated
with an increased risk of developing cutaneous malignancies. Clinical outcomes for these …

Haemophagocytic lymphohistiocytosis (HLH) is a rare complication of immune checkpoint
inhibitor therapy. A 55-year-old male with stable chronic lymphocytic leukemia presented …

Immune checkpoint inhibitors (ICIs) have revolutionised the treatment landscape across
many solid organ malignancies and form part of routine clinical practice in many tumours. As …